This section contains medical information intended for healthcare professionals. It is the responsibility of healthcare professionals at their own discretion to communicate or deliver safety information addressed to patients. By closing this window, you confirm that you are a healthcare professional.
You're about to change the country setting. Some products or services may differ based on regional availability.
If you are logged in, you will be logged out automatically, and you'll need to log back in after the switch.
Are you sure you want to continue?
CancelYes, switch country
Products
Products
These materials have been approved and / or notified to regulatory authorities. Please use the material for your respective country.
These materials are not intended to condition the prescription, use, promotion, sale, recommendation, indication or approval of any Roche product or any concession of benefits to Roche.
Pharmacovigilance
Roche always makes sure to ensure the effectiveness of its medical treatments. If you know of any adverse event due to the use of Roche medicines, please contact us.
This activity to minimize risks to public health consists in a Pregnancy Prevention Program designed to minimize the risk of teratogenicity and provide education on the risk of teratogenicity and the recommended contraceptive measures to prevent fetal exposure. The objectives are to prevent exposure to vismodegib in pregnant women and inform patients of the teratogenic risks to the fetus that are associated with vismodegib use.
The objective of the material is to intensify communication and education in patients about the significant potential risk of bleeding / hemorrhage that threatens their lives; due to misinterpretation of standard coagulation examinations or tests, which are not reliable in patients treated with Emicizumab.
Objective: This material aims to remind healthcare professionals about the correct technique for administering the MabThera SC, its storage; as well as emphasizing the differences in packaging between the intravenous and subcutaneous formulation, in order to minimize the possibility of medication errors. Finally, we wish to highlight that the subcutaneous formulation is approved only for the use of Non-Hodgkin's Lymphoma. All the information contained in the material is indicated in the label and approved by the Health Authority.
This activity to minimize risks to public health aims to remind patients that Roaccutane® is totally contraindicated in women with the potential to have children unless the patient with the condition of the Pregnancy Prevention Program (PPP) as detailed in the product information. To avoid fetal exposure to Roaccutane®, providing educational materials to patients prescribed Roaccutane® to reinforce patient’s understanding of the risk of birth defects and key elements of the PPP such as the critical importance of effective contraception methods while taking Roaccutane®.
Objetive: This material aims to inform patient/carers adequately on the risks, the key signs and symptoms of those risks, and when to seek urgent attention from their physician with the objective to minimize the important identified risks of infectious endophthalmitis and intraocular inflammation; and to promote communication between the patient and their physician.
Material created by Roche. | All rights reserved - reproduction in whole or in part is prohibited without the prior written authorization of Roche Servicios S.A.
This material may contain information regarding investigational medicinal products or active substances, or indications not yet approved in your country, with the aim of providing medical and/or scientific information of interest to healthcare professionals. Roche does not recommend the use of any product in any indication, dosage, or route of administration that is not clearly listed in the product insert or marketing authorization approved by the local regulatory authority.
For healthcare professionals only.
This product is approved in all countries in the Caribbean, Central America and Venezuela region.
Subscribe to Our Newsletter
Want to stay up-to-date on the latest news in medical innovation? Receive all the latest scientific research and technologies revolutionizing the healthcare sector directly to your inbox.
Register and select your areas of interest. Stay up to date!
Subscribe
Subscribe
Supporting healthcare professionals every day
By clicking "Continue" you will access content that may not be owned by Roche. If so, Roche assumes no responsibility for the access, use and content of this website.
If you want to stay on Dialogo Roche, click on "Close".
Restricted
Bookmarking is available only for logged-in users.
